Revelation Biosciences (REVB) to Release Quarterly Earnings on Thursday

Revelation Biosciences (NASDAQ:REVB) is expected to be posting its results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($3.66) per share for the quarter.

Revelation Biosciences Trading Up 4.4%

REVB stock opened at $1.41 on Thursday. The firm has a market cap of $9.73 million, a P/E ratio of -0.01 and a beta of -0.11. Revelation Biosciences has a 12-month low of $1.29 and a 12-month high of $46.31. The stock’s 50 day simple moving average is $2.63 and its 200 day simple moving average is $5.01.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently raised its position in Revelation Biosciences stock. Armistice Capital LLC grew its holdings in Revelation Biosciences, Inc. (NASDAQ:REVB) by 442.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 434,272 shares of the company’s stock after buying an additional 354,272 shares during the quarter. Armistice Capital LLC owned 6.29% of Revelation Biosciences worth $347,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 12.80% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e)” rating on shares of Revelation Biosciences in a report on Monday, December 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Revelation Biosciences has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.